These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 6116757)

  • 1. Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains.
    Al-Dabbagh SG; Idle JR; Smith RL
    J Pharm Pharmacol; 1981 Mar; 33(3):161-4. PubMed ID: 6116757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.
    Veronese ME; McLean S
    Eur J Clin Pharmacol; 1991; 40(6):547-52. PubMed ID: 1884734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methoxyphenamine metabolism in rat models of human debrisoquine phenotypes.
    Roy SD; Hawes EM; McKay G; Hubbard JW; Midha KK
    Can J Physiol Pharmacol; 1985 Jul; 63(7):778-81. PubMed ID: 3876145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man.
    Zysset T; Zeugin T; Küpfer A
    Biochem Pharmacol; 1988 Aug; 37(16):3155-60. PubMed ID: 3401246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphic ochratoxin A hydroxylation in rat strains phenotyped as poor and extensive metabolizers of debrisoquine.
    Castegnaro M; Bartsch H; Bereziat JC; Arvela P; Michelon J; Broussolle L
    Xenobiotica; 1989 Feb; 19(2):225-30. PubMed ID: 2786290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstrain comparison of hepatic and renal microsomal carcinogen metabolism and liver S9-mediated mutagenicity in DA and Lewis rats phenotyped as poor and extensive metabolizers of debrisoquine.
    Hietanen E; Malaveille C; Camus AM; Béréziat JC; Brun G; Castegnaro M; Michelon J; Idle JR; Bartsch H
    Drug Metab Dispos; 1986; 14(1):118-26. PubMed ID: 2868854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism.
    Muralidharan G; Midha KK; McKay G; Hawes EM; Inaba T
    Xenobiotica; 1989 Feb; 19(2):189-97. PubMed ID: 2786289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition.
    Devonshire HW; Kong I; Cooper M; Sloan TP; Idle JR; Smith RL
    Br J Clin Pharmacol; 1983 Aug; 16(2):157-66. PubMed ID: 6615690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipyrine metabolism in female Lewis and Dark Agouti strains of rats, which are extensive and poor metabolizers of debrisoquine, respectively.
    Tanaka E; Kobayashi S; Uchida E; Oguchi K; Yasuhara H
    Jpn J Pharmacol; 1989 Mar; 49(3):433-5. PubMed ID: 2747044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically determined oxidation capacity and the disposition of debrisoquine.
    Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
    Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphism of carbon oxidation of drugs and clinical implications.
    Sloan TP; Mahgoub A; Lancaster R; Idle JR; Smith RL
    Br Med J; 1978 Sep; 2(6138):655-7. PubMed ID: 151576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphic debrisoquine and mephenytoin hydroxylation in patients with pulmonary hypertension of vascular origin after aminorex fumarate.
    Saner H; Gurtner HP; Preisig R; Küpfer A
    Eur J Clin Pharmacol; 1986; 31(4):437-42. PubMed ID: 3816924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains.
    Küpfer A; Al-Dabbagh SG; Ritchie JC; Idle JR; Smith RL
    Biochem Pharmacol; 1982 Oct; 31(20):3193-9. PubMed ID: 7150348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
    Sloan TP; Idle JR; Smith RL
    Clin Pharmacol Ther; 1981 Apr; 29(4):493-7. PubMed ID: 7471615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of dextromethorphan O-demethylation in man.
    Küpfer A; Schmid B; Pfaff G
    Xenobiotica; 1986 May; 16(5):421-33. PubMed ID: 3739367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
    Peart GF; Boutagy J; Shenfield GM
    Eur J Clin Pharmacol; 1987; 33(4):397-402. PubMed ID: 3443146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxylation of debrisoquine using perfused liver isolated from Sprague Dawley and DA rats: comparison with in-vivo results.
    Vincent-Viry M; Deshayes S; Mothe O; Siest G; Galteau MM
    J Pharm Pharmacol; 1988 Oct; 40(10):695-700. PubMed ID: 2907535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.
    Oram M; Wilson K; Burnett D; Al-Dabbagh SG; Idle JR; Smith RL
    Eur J Clin Pharmacol; 1982; 23(2):147-50. PubMed ID: 7140803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
    McGourty JC; Silas JH; Lennard MS; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1985 Dec; 20(6):555-66. PubMed ID: 2868742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.